https://health-union.com/wp-content/uploads/2023/04/1468x560_Rare-Disease-Blog-Post-on-Mental-Health.png
1120
2936
Stephen Wilson
/wp-content/uploads/2021/06/health-union-logo-07-300x90-1.png
Stephen Wilson2023-04-24 14:41:472024-08-22 12:54:43Rare Conditions: The Impact of Mental Health ConcernsHealth Union’s data-driven industry conversations help pharma make smarter, more effective decisions.
Check out our latest thought leadership pieces below.
https://health-union.com/wp-content/uploads/2023/04/1468x560_Rare-Disease-Blog-Post-on-Mental-Health.png
1120
2936
Stephen Wilson
/wp-content/uploads/2021/06/health-union-logo-07-300x90-1.png
Stephen Wilson2023-04-24 14:41:472024-08-22 12:54:43Rare Conditions: The Impact of Mental Health Concerns
https://health-union.com/wp-content/uploads/2023/04/HU-Featured-SHA-Interview-comp-image-033123.jpg
840
2202
Felicia Brecher
/wp-content/uploads/2021/06/health-union-logo-07-300x90-1.png
Felicia Brecher2023-04-11 08:32:322024-08-22 15:16:53Social Health Awards: The Mutual Value and Impact for Patients and Industry
https://health-union.com/wp-content/uploads/2023/03/An-interview-with-Erin-Willis-Julie-feature.jpg
763
2000
Lina Kirby
/wp-content/uploads/2021/06/health-union-logo-07-300x90-1.png
Lina Kirby2023-03-24 09:22:472024-08-22 15:29:45Expert Perspectives: A Conversation on the Role of Responsible Patient Leadership
https://health-union.com/wp-content/uploads/2023/03/Beyond-the-Patient-How-the-Whole-Person-Influences-Health-Decisions-Blog1428-×-560.png
1120
2856
Felicia Brecher
/wp-content/uploads/2021/06/health-union-logo-07-300x90-1.png
Felicia Brecher2023-03-23 14:58:552024-08-22 15:53:18Beyond the Patient: How the Whole Person Influences Health Decisions
Differences in DMT treatment experiences among people with MS: Here’s what patients say
For many people living with multiple sclerosis (MS), treatment decisions can often be nuanced and complicated. In April of 2018, the American Academy of Neurology (AAN) released new guidelines about when to begin, change, and end disease-modifying therapies (DMTs) for MS patients. MS In America 2018 results may help the healthcare industry gain a broader understanding of people’s experiences, or lack thereof, with DMTs and other MS treatment options.
WHITEPAPER DOWNLOAD: #authenticity How Social Media Can Fuel Growth-Oriented, Sustainable Online Communities
Download the full free whitepaper, “#authenticity How Social Media Can Fuel Growth-Oriented, Sustainable Online Communities”
Patient Centricity Starts With Patients: Closing the Trial Recruitment Gap
There is a lot of talk in the industry about patient centricity, but is it the reality? We talk about putting the needs of patients first and keeping them central in the business decisions we make across the healthcare industry. However, as we discussed on a panel at this year’s DIA 2018 Global Annual Meeting, somehow in the effort to amplify patient centricity, a critical voice is often underrepresented—the voice of the patient.
Building Relationships vs. Publishing Content: Reflecting on the Renewed Interest In Migraine Disease
A new class of migraine drugs, called anti-CGRPs (calcitonin gene-related peptide) are expected to reinvigorate a market that has been largely dormant for some time. Four biopharma companies, Amgen, Teva, Lilly and Alder are entering the fray. Not surprisingly, the intense competition and pharma investment associated with this market dynamic has led traditional “eyeball driven” publishers, like WebMD, Everyday Health and others on a quest to offer substantially more migraine-related content in reaction to this market opportunity.